Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New breast cancer findings from A. Vazquezmartin and co-researchers published
December 18th, 2007
According to recent research from Spain, "Elucidating the mechanisms underlying resistance to the human epidermal growth factor receptor 2 (HER2)targeted antibody trastuzumab (Tzb; Herceptin (TM)) is a major challenge that is beginning to be addressed. This dilemma is becoming increasingly important as recent studies strongly support a role for Tzb in the adjuvant setting for HER2-overexpressing early-stage breast cancers." "We previously reported that pharmacological and RNA interference-induced inhibition of tumor-associated fatty acid synthase (FASN; Oncogenic antigen-519), a key metabolic enzyme catalyzing the synthesis of long-chain saturated fatty acids,...
Source: Cancer Weekly (2007-12-18)
|
